(Q38196042)

30 August 2017

1 reference

title

Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology (English)

1 reference

enzyme replacement therapy

30 August 2017

main subject

0 references

author name string

Gregory A Grabowski

series ordinal

1

1 reference

30 August 2017

Myriam Golembo

series ordinal

2

1 reference

30 August 2017

Yoseph Shaaltiel

series ordinal

3

1 reference

30 August 2017

publication date

2 March 2014

1 reference

Molecular Genetics and Metabolism

30 August 2017

published in

1 reference

30 August 2017

volume

112

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

1-8

1 reference

Recommendations on diagnosis, treatment, and monitoring for Gaucher disease

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Velaglucerase alfa in the treatment of Gaucher disease type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Plant cell cultures for the production of recombinant proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Is the drought over for pharming?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Plant-derived vaccines and other therapeutics produced in contained systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Posttranslational modification of therapeutic proteins in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Expression systems for therapeutic glycoprotein production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Use of baculovirus expression system for generation of virus-like particles: successes and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Plant-specific glycosylation patterns in the context of therapeutic protein production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Imaging of enzyme replacement therapy using PET

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

N-glycoprotein biosynthesis in plants: recent developments and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Structural comparison of differently glycosylated forms of acid-β-glucosidase, the defective enzyme in Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

The most transformative drugs of the past 25 years: a survey of physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Replacement therapy with imiglucerase for type 1 Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.02.011

10.1016/J.YMGME.2014.02.011

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference